AstraZeneca Pharma India Ltd. - Research Center
506820 ASTRAZEN Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 20 | Mar ' 20 | Sep ' 19 | Sep ' 18 | Sep ' 17 | |
|---|---|---|---|---|---|
| Sales | 403.05 | 418.76 | 413.04 | 322.80 | 291.74 |
| Operating profit | 64.33 | 51.55 | 69.12 | 24.04 | 41.87 |
| Interest | 0.55 | 0.54 | 0.58 | - | - |
| Gross profit | 71.14 | 57.85 | 74.69 | 30.82 | 49.02 |
| EPS (Rs) | 17.99 | 14.51 | 14.37 | 6.21 | 13.27 |
Half yearly
results in details
| Sep ' 20 | Mar ' 20 | Sep ' 19 | Sep ' 18 | Sep ' 17 | |
|---|---|---|---|---|---|
| Other income | 7.36 | 6.84 | 6.15 | 6.78 | 7.15 |
| Stock adjustment | -11.12 | -41.11 | 1.90 | 32.38 | -16.22 |
| Raw material | 44.83 | 38.17 | 32.04 | 26.34 | 8.60 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 111.99 | 133.80 | 102.90 | 88.02 | 71.34 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | 20.73 | 24.76 | 31.00 | 40.30 | 27.12 |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 172.30 | 211.58 | 176.09 | 111.71 | 159.03 |
| Provisions made | - | - | - | - | - |
| Depreciation | 9.18 | 9.32 | 9.27 | 7.22 | 7.46 |
| Taxation | 16.98 | 12.25 | 29.49 | 8.07 | 8.38 |
| Net profit / loss | 44.97 | 36.28 | 35.93 | 15.53 | 33.18 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 15.96 | 12.31 | 16.73 | 7.45 | 14.35 |
| GPM (%) | 17.33 | 13.59 | 17.82 | 9.35 | 16.40 |
| NPM (%) | 10.96 | 8.52 | 8.57 | 4.71 | 11.10 |
© 2021 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis